Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 598

1.

Optimising the design of phase II oncology trials: the importance of randomisation.

Ratain MJ, Sargent DJ.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

PMID:
19059773
2.

[Randomised phase II trials in oncology].

Piedbois P.

Bull Cancer. 2007 Nov;94(11):953-6. French.

PMID:
18055312
3.

Optimizing randomized phase II trials assessing tumor progression.

Stone A, Wheeler C, Carroll K, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):146-52. Epub 2006 May 19.

PMID:
16807129
4.

Improving the design of phase II trials of cytostatic anticancer agents.

Stone A, Wheeler C, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):138-45. Epub 2006 Jul 14. Review.

PMID:
16843736
5.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ.

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. Epub 2007 Sep 25. No abstract available.

6.

Design issues of randomized phase II trials and a proposal for phase II screening trials.

Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA.

J Clin Oncol. 2005 Oct 1;23(28):7199-206.

7.

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ.

J Clin Oncol. 2010 Apr 10;28(11):1936-41. doi: 10.1200/JCO.2009.25.5489. Epub 2010 Mar 8.

8.

Novel designs and end points for phase II clinical trials.

Adjei AA, Christian M, Ivy P.

Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Review.

9.

Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.

Pond GR, Abbasi S.

Clin Trials. 2011 Jun;8(3):260-9. doi: 10.1177/1740774511401764. Epub 2011 Apr 20.

PMID:
21511687
10.

Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?

Bradbury P, Seymour L.

Cancer J. 2009 Sep-Oct;15(5):354-60. doi: 10.1097/PPO.0b013e3181b9c506. Review.

PMID:
19826353
11.

Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.

Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9. Review.

12.

[New trends in assessment in anticancer treatments by phase II clinical trials].

Medioni JR, Rycke YD, Asselain B.

Bull Cancer. 2000 Jul;87(7-8):551-6. Review. French.

PMID:
10969213
13.

An adaptive design for phase II non-oncology dose selection clinical trials.

Su Z.

Clin Drug Investig. 2010;30(6):397-403. doi: 10.2165/11533340-000000000-00000.

PMID:
20373828
14.

Other paradigms: randomized discontinuation trial design.

Stadler W.

Cancer J. 2009 Sep-Oct;15(5):431-4. doi: 10.1097/PPO.0b013e3181bd0431. Review.

PMID:
19826364
15.
16.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G; PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

PMID:
21435858
17.

The use of unequal randomisation ratios in clinical trials: a review.

Dumville JC, Hahn S, Miles JN, Torgerson DJ.

Contemp Clin Trials. 2006 Feb;27(1):1-12. Epub 2005 Oct 19. Review.

PMID:
16236557
18.

A flexible multi-stage design for phase II oncology trials.

Tan MT, Xiong X.

Pharm Stat. 2011 Jul-Aug;10(4):369-73. doi: 10.1002/pst.478. Epub 2010 Dec 8.

PMID:
22328328
19.

Randomized phase II trials: misleading and unreliable.

Stewart DJ.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20. No abstract available.

20.

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.

Fazzari M, Heller G, Scher HI.

Control Clin Trials. 2000 Aug;21(4):360-8.

PMID:
10913810
Items per page

Supplemental Content

Write to the Help Desk